Overweight AdultsCHIA-PGANCT07797049
Chia Seed Impact on Postprandial Glycemia and Appetite in Overweight Adults
A study testing Chia Seed (Salvia hispanica L.) Beverage in people with Overweight Adults and Postprandial Glycemia, run by University of Veterinary and Animal Sciences, Lahore - Pakistan at 1 site in Pakistan.
Trial summary
Overweight and obesity affect nearly 2.5 billion adults worldwide and increase cardiometabolic risk. Postprandial glucose excursions are influenced by diet and inactivity and predict metabolic disorders, while South Asians, particularly Pakistanis, are more vulnerable due to genetic and lifestyle factors and processed… Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Overweight Adults, Postprandial Glycemia, Appetite Response
- What is being tested?
- Chia Seed (Salvia hispanica L.) Beverage
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 sitePakistan
- Study dates
- 28 Aug 2026to 15 Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age: 18-40 years
- BMI: 25-29.9 kg/m²
- Male and female participants
- Normoglycemic participants
Who cannot join
- Pregnant
- Smoking
- Prediabetes/diabetes Medication use Chronic disease Supplementation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site
University of Veterinary and Animal Sciences Lahore
Lahore, Punjab Province, 54000
Univeristy of Veterinary and Animal Sciences, +92-42-99211374, webmaster@uvas.edu.pk
Kaniz Fatima Khalid Mir, Mphil Food and Nutrition
About this study
Official title: Impact of Chia Seed (Salvia Hispanica L.) Ingestion on Postprandial Glycemia and Appetite in Overweight Adults: A Randomized Controlled Crossover Trial
Overweight and obesity affect nearly 2.5 billion adults worldwide and increase cardiometabolic risk. Postprandial glucose excursions are influenced by diet and inactivity and predict metabolic disorders, while South Asians, particularly Pakistanis, are more vulnerable due to genetic and lifestyle factors and processed diets. This study evaluates the impact of chia seed (Salvia hispanica L.) ingestion on postprandial glycemia and appetite in overweight adults, supporting UN Sustainable Development Goal 3 (Good Health and Well-being).
A randomized controlled crossover trial will be conducted among 30 overweight adults (BMI 25-29.9 kg/m²), aged 18-40 years. Participants will undergo control and intervention phases separated by a 14-day washout. The control beverage will contain 50 g glucose in 250 mL water, while the intervention beverage will contain the same beverage supplemented with 30 g chia seeds. Glucose response will be assessed using incremental area under the curve (iAUC) by the trapezoidal method, with appetite response also evaluated. Data will be analyzed using SPSS version 25; baseline characteristics will be presented as mean ± SD, and between-group differences will be assessed using a linear mixed model at p < 0.05. Chia seed ingestion is expected to reduce postprandial blood glucose and improve appetite control.
- Conditions
- Overweight Adults, Postprandial Glycemia, Appetite Response
- Being tested
- Chia Seed (Salvia hispanica L.) Beverage
- Keywords
- Chia seed, Postprandial glycemia, Appetite, Overweight adults, Randomized controlled crossover trial, Salvia hispanica
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Chia Seed (Salvia hispanica L.) BeverageDietary supplement
Also called Glucose Beverage
Participants will consume a standardized beverage containing 50 g glucose dissolved in 250 mL water, without chia seeds or any other fiber-containing ingredient. This beverage will serve as the control condition for comparison with the chia seed-supplemented glucose beverage.
| Study group | Role | What they receive |
|---|---|---|
| Control arm: 50 g glucose in 250 mL water | Active comparator | Participants will consume a standardized control beverage containing 50 g glucose dissolved in 250 mL water, with no chia seeds. Postprandial blood glucose and appetite responses will be assessed following consumption. Receives: Dietary Supplement: Chia Seed (Salvia hispanica L.) Beverage |
| Intervention arm: 50 g glucose + 30 g chia seeds in 250 mL water | Active comparator | Participants will consume a standardized beverage containing 50 g glucose dissolved in 250 mL water supplemented with 30 g chia seeds (Salvia hispanica L.). Postprandial blood glucose and appetite responses will be assessed following consumption. Receives: Dietary Supplement: Chia Seed (Salvia hispanica L.) Beverage |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postprandial Blood Glucose
Incremental area under the blood glucose curve (iAUC) will be calculated from capillary blood glucose concentrations measured using a portable blood glucose meter (glucometer) from finger-prick blood samples at baseline (0 minutes) and at 15, 30, 45, 60, 90, and 120 minutes following beverage consumption. The iAUC will be calculated using the trapezoidal method over the 120-minute postprandial period, with fasting baseline glucose concentration used as the reference. Areas below the baseline will not contribute to the iAUC. The iAUC will be expressed in mmol·min/L. A lower iAUC indicates a lower overall postprandial glycemic response over 120 minutes. The change in iAUC between the intervention (50 g glucose + 30 g chia seeds) and control (50 g glucose) beverages will be compared.
Measured: 5 weeks
Secondary outcomes (1)
Appetite Response
Appetite will be assessed using 100-mm Visual Analog Scales for hunger, fullness, desire to eat, and prospective food consumption. Each scale ranges from 0 to 100 mm. For hunger, desire to eat, and prospective food consumption, 0 indicates the lowest intensity ("not at all"/"nothing at all") and 100 indicates the highest intensity ("extremely"/"an extremely large amount"); higher scores indicate greater appetite. For fullness, 0 indicates not at all full and 100 indicates extremely full; higher scores indicate greater fullness and better appetite suppression.
Measured: 5 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2026
- Study start28 Aug 2026 (estimated)
- Primary completion28 Sep 2026 (estimated)
- Study completion15 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Overweight AdultsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Veterinary and Animal Sciences, Lahore - Pakistan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Qaisar Raza, University of Veterinary and Animal Sciences, Lahore - Pakistan
- Investigators
- Dr. Qaisar Raza, Principal investigator, University of Veterinary and Animal Sciences 54000 Lahore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07797049
- Sponsor's protocol ID
- 456/IRC/BMR
- Acronym
- CHIA-PGA
- Status last verified
- Aug 2026
- First submitted
- 24 Aug 2026
- Last updated
- 1 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared with other researchers due to participant confidentiality and privacy considerations. Only aggregated, de-identified study results will be reported and shared.
Publications
Arefhosseini S, Parimi M, Tutunchi H, Ebrahimi-Mameghani M. The effects of salvia hispanica (chia seeds) on insulin sensitivity, hematological inflammatory indices and liver function in obese patients with non-alcoholic fatty liver disease (NAFLD). Nutr Metab (Lond). 2025 Oct 22;22(1):125. doi: 10.1186/s12986-025-01012-0.
PubMed 41126329
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Chia Seed (Salvia Hispanica L.) Ingestion on Postprandial Glycemia and Appetite in Overweight Adults: A Randomized Controlled Crossover Trial
- ClinicalTrials.gov ID
- NCT07797049
- Acronym / sponsor ID
- CHIA-PGA / 456/IRC/BMR
- Conditions
- Overweight Adults, Postprandial Glycemia, Appetite Response
- Keywords
- Chia seed, Postprandial glycemia, Appetite, Overweight adults, Randomized controlled crossover trial, Salvia hispanica
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- University of Veterinary and Animal Sciences, Lahore - PakistanUniversity, hospital or other
- Study start
- 28 Aug 2026 (estimated)
- Primary completion
- 28 Sep 2026 (estimated)
- Study completion
- 15 Oct 2026 (estimated)
- First posted
- 1 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Overweight and obesity affect nearly 2.5 billion adults worldwide and increase cardiometabolic risk. Postprandial glucose excursions are influenced by diet and inactivity and predict metabolic disorders, while South Asians, particularly Pakistanis, are more vulnerable due to genetic and lifestyle factors and processed diets. This study evaluates the impact of chia seed (Salvia hispanica L.) ingestion on postprandial glycemia and appetite in overweight adults, supporting UN Sustainable Development Goal 3 (Good Health and Well-being).
A randomized controlled crossover trial will be conducted among 30 overweight adults (BMI 25-29.9 kg/m²), aged 18-40 years. Participants will undergo control and intervention phases separated by a 14-day washout. The control beverage will contain 50 g glucose in 250 mL water, while the intervention beverage will contain the same beverage supplemented with 30 g chia seeds. Glucose response will be assessed using incremental area under the curve (iAUC) by the trapezoidal method, with appetite response also evaluated. Data will be analyzed using SPSS version 25; baseline characteristics will be presented as mean ± SD, and between-group differences will be assessed using a linear mixed model at p < 0.05. Chia seed ingestion is expected to reduce postprandial blood glucose and improve appetite control.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control arm: 50 g glucose in 250 mL water | Active comparator | Dietary Supplement: Chia Seed (Salvia hispanica L.) BeverageParticipants will consume a standardized control beverage containing 50 g glucose dissolved in 250 mL water, with no chia seeds. Postprandial blood glucose and appetite responses will be assessed following consumption. |
| Intervention arm: 50 g glucose + 30 g chia seeds in 250 mL water | Active comparator | Dietary Supplement: Chia Seed (Salvia hispanica L.) BeverageParticipants will consume a standardized beverage containing 50 g glucose dissolved in 250 mL water supplemented with 30 g chia seeds (Salvia hispanica L.). Postprandial blood glucose and appetite responses will be assessed following consumption. |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Age: 18-40 years
- BMI: 25-29.9 kg/m²
- Male and female participants
- Normoglycemic participants
Key exclusion criteria (3 listed)
- Pregnant
- Smoking
- Prediabetes/diabetes Medication use Chronic disease Supplementation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Chia Seed (Salvia hispanica L.) BeverageAlso: Glucose BeverageParticipants will consume a standardized beverage containing 50 g glucose dissolved in 250 mL water, without chia seeds or any other fiber-containing ingredient. This beverage will serve as the control condition for comparison with the chia seed-supplemented glucose beverage. | Dietary supplement | Control arm: 50 g glucose in 250 mL water, Intervention arm: 50 g glucose + 30 g chia seeds in 250 mL water |
Primary outcome
Postprandial Blood Glucose
Time frame: 5 weeks
Incremental area under the blood glucose curve (iAUC) will be calculated from capillary blood glucose concentrations measured using a portable blood glucose meter (glucometer) from finger-prick blood samples at baseline (0 minutes) and at 15, 30, 45, 60, 90, and 120 minutes following beverage consumption. The iAUC will be calculated using the trapezoidal method over the 120-minute postprandial period, with fasting baseline glucose concentration used as the reference. Areas below the baseline will not contribute to the iAUC. The iAUC will be expressed in mmol·min/L. A lower iAUC indicates a lower overall postprandial glycemic response over 120 minutes. The change in iAUC between the intervention (50 g glucose + 30 g chia seeds) and control (50 g glucose) beverages will be compared.
1 secondary outcome
Appetite Response
Time frame: 5 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2026.
- Background: PubMed 41126329Arefhosseini S, Parimi M, Tutunchi H, Ebrahimi-Mameghani M. The effects of salvia hispanica (chia seeds) on insulin sensitivity, hematological inflammatory indices and liver function in obese patients with non-alcoholic fatty liver disease (NAFLD). Nutr Metab (Lond). 2025 Oct 22;22(1):125. doi: 10.1186/s12986-025-01012-0.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data will not be shared with other researchers due to participant confidentiality and privacy considerations. Only aggregated, de-identified study results will be reported and shared.
Related trials for Overweight Adults
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity
RecruitingPhase 3
A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)
Obesity
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dr. Qaisar Raza principal investigator
University of Veterinary and Animal Sciences 54000 Lahore
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Chia Seed (Salvia hispanica L.) Beverage in people with Overweight Adults and Postprandial Glycemia, run by University of Veterinary and Animal Sciences, Lahore - Pakistan at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kaniz Fatima Khalid Mir, Mphil Food and Nutrition (+923004629606, fatimamir092@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postprandial Blood Glucose (time frame: 5 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07797049, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.